News | September 03, 2025
Novartis Leqvio demonstrates strong LDL-C goal achievement with reduced muscle pain
The trial is the largest to date evaluating Leqvio and the first to focus on patient-centered outcomes
The trial is the largest to date evaluating Leqvio and the first to focus on patient-centered outcomes
ITP is a disease of complex immune dysregulation leading to low platelet counts, bleeding, and reduced quality of life
The FDA also expanded Repatha’s use as monotherapy to include patients with homozygous familial hypercholesterolemia
Guidelines aim to establish state-regulated veterinary blood banks
Inclacumab was generally well tolerated in THRIVE-131
Glucagon is indicated for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes mellitus
The submission is supported by positive results from the Phase 3 AMPLIFY trial
Both these products will be manufactured at Lupin’s Injectable facility at Nagpur, India
Ibrutinib tablets will be produced at Zydus Lifesciences Ltd (SEZ), Ahmedabad
Reblozyl is a standard of care for the first-line treatment of anemia without previous erythropoiesis stimulating agent use
Subscribe To Our Newsletter & Stay Updated
